Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced a partnership with The University of Alabama Culverhouse College of Business to launch its ai² Future Labs program. The initiative connects university students with biopharmaceutical strategy and business development projects.
The program pairs student teams with Apimeds mentors to identify and evaluate opportunities to advance development projects previously abandoned by the pharmaceutical industry. Students participating in the STEM Path to the MBA program will work on real-world projects focused on improving human health outcomes.
According to the company, students will gain experience in market analysis, FDA regulations, clinical development requirements, competitive positioning, intellectual property considerations, and commercialization planning. Top-performing teams at participating institutions will be eligible for paid internships or consulting opportunities with Apimeds.
“We’re excited to welcome The University of Alabama and their STEM Path to the MBA students to the Future Labs program,” said Erik Emerson, CEO of Apimeds. “UA will be the first of a select group of academic institutions we partner with to identify opportunities to improve patient care by reexamining promising projects.”
Brian Peters, SVP of the ai² Division at Apimeds Pharmaceuticals, described the program as a way to uncover development opportunities while giving students practical experience in the business side of biopharmaceuticals.
Rob Morgan, Director of the STEM Path and CREATE Path to the MBA programs at The University of Alabama, said the partnership provides students with experience contributing to a biopharmaceutical company’s success.
Future Labs operates as part of Apimeds’ ai² innovation platform. Apimeds is a clinical-stage biopharmaceutical company developing non-opioid, biologic-based therapies for pain management, with its lead product candidate Apitox in late-stage clinical development for osteoarthritis of the knee.
Read more on StreetInsider.com
